What is Immucillin H used for?

Immucillin H is indicated for Peripheral T-cell lymphoma.

Who makes Immucillin H?

Immucillin H is developed by Mundi Pharma.

What development phase is Immucillin H in?

Immucillin H is FDA-approved (marketed).

What is the generic name of Immucillin H?

FORODESINE is the generic (nonproprietary) name of Immucillin H.

Last reviewed 2026-04-20 · How we verify

Immucillin H (FORODESINE)

Mundi Pharma · FDA-approved approved Small molecule Quality 24/100

At a glance

Generic name	FORODESINE
Sponsor	Mundi Pharma
Target	Purine nucleoside phosphorylase
Modality	Small molecule
Therapeutic area	Oncology
Phase	FDA-approved
First approval	2017

Approved indications

Peripheral T-cell lymphoma

Common side effects

No common side effects on file.

Key clinical trials

Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients (PHASE1,PHASE2)
Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies (PHASE1)
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma (PHASE1)
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma (PHASE1,PHASE2)
BCX-1777 in Treating Patients With Refractory Cancer (PHASE1)
Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. (PHASE1,PHASE2)
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) (PHASE2)
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Immucillin H CI brief — competitive landscape report
Immucillin H updates RSS · CI watch RSS
Mundi Pharma portfolio CI